# To Evaluate the Efficacy and Safety of SAL056 for Postmenopausal Women With Osteoporosis at High Fracture Risk

> **NCT07028320** · PHASE3 · COMPLETED · sponsor: **Shenzhen Salubris Pharmaceuticals Co., Ltd.** · enrollment: 493 (actual)

## Conditions studied

- Postmenopausal Women With Osteoporosis

## Interventions

- **DRUG:** SAL056 (56.5μg)
- **DRUG:** Alendronate

## Key facts

- **NCT ID:** NCT07028320
- **Lead sponsor:** Shenzhen Salubris Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-03
- **Primary completion:** 2023-12-30
- **Final completion:** 2024-05-20
- **Target enrollment:** 493 (ACTUAL)
- **Last updated:** 2025-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07028320

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07028320, "To Evaluate the Efficacy and Safety of SAL056 for Postmenopausal Women With Osteoporosis at High Fracture Risk". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07028320. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*